Results 111 to 120 of about 1,308 (200)

Effects of Ranolazine on Vascular Adrenergic Receptors in Rabbit Aorta. [PDF]

Int J Med Sci
Jorda A, Mauricio MD, Guerra-Ojeda S, Vila JM, Valles SL, Aldasoro M.   +5 more
europepmc   +1 more source

Mirabegron and Intradetrusor Onabotulinumtoxina for Overactive Bladder in Parkinson's Disease: A Systematic Review and Meta-Analysis. [PDF]

Neurourol Urodyn
Arshad H, Nuha R, Khashaba S, Gillatt D, Lewis SJG.   +4 more
europepmc   +1 more source

Trends and Racial/Ethnic Disparities in Pharmacologic and Surgical Management of Treated Female Patients With Urinary Incontinence. [PDF]

Neurourol Urodyn
Almadfaa RO, Wigle PR, Lin AC, Hardee A, Guo JJ, Hincapie AL.   +5 more
europepmc   +1 more source

Validated comprehensive RP HPLC approach for separation and quantification of solifenacin and mirabegron in the presence of their degradation products. [PDF]

Sci Rep
Kamel EB, Badrawy M, Nour IM.
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Quality of Life in Children With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kümmerli S, Elviro CF, Regamey N, Mornand A, Faouzi M, Rochat I, Blanchon S.   +6 more
europepmc   +1 more source

Mirabegron exhibits antibacterial and Immunomodulatory activities demonstrated by in vitro and in vivo studies. [PDF]

Sci Rep
Ahmed EA, Abd-Eldayem AM.
europepmc   +1 more source

Combined inhibition of BETs and HDACs as a potential epigenetics-based therapy for malignant rhabdoid tumor. [PDF]

Cell Death Dis
Zhu L, Li Y, Wen Y, Wen J, Zhang J, Min L, Li C, Peng Q, Wang L, Li A, Liu Z, Wang X.   +11 more
europepmc   +1 more source

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry): Protocol for an Open-Label Prospective Randomized Trial. [PDF]

JMIR Res Protoc
Svendsen AM, Hagstrøm S, Kamperis K, Andersen AE, Henneberg NC, Van Batavia J, Olesen AE, Borch L.   +7 more
europepmc   +1 more source

Distinct Conformations of Mirabegron Determined by MicroED. [PDF]

Adv Sci (Weinh), 2023
Lin J, Unge J, Gonen T.
europepmc   +1 more source

Clinical CYP2D6-Mediated Pharmacokinetic Drug-Drug Interactions of DA-8010 with Paroxetine or Mirabegron in Healthy Korean Participants. [PDF]

Drug Des Devel Ther
Ryu H, Cho JY, Lee DY, Lee S.
europepmc   +1 more source